# Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases

> **NCT00811174** · PHASE3 · TERMINATED · sponsor: **Octapharma** · enrollment: 5 (actual)

## Conditions studied

- Immunologic Deficiency Syndromes

## Interventions

- **DRUG:** Octagam 10%

## Key facts

- **NCT ID:** NCT00811174
- **Lead sponsor:** Octapharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Due to limited data available, efficacy, and PK analyses were not performed.
- **Last updated:** 2017-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00811174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00811174, "Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00811174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*